医疗失效模式与效应分析在神经重症患者CVAD-MARSI管理中的应用
Application of Health Care Failure Mode and Effects Analysis in CVAD-MARSI Management of Neurocritical Patients
郝俊丽 1于航娜 1郭亚杰 2郭东波 3杜瑞云 4杨春艳5
作者信息
- 1. 郑州大学附属肿瘤医院/河南省肿瘤医院乳腺外科,河南郑州 450008
- 2. 郑州大学附属肿瘤医院/河南省肿瘤医院胸外科,河南郑州 450008
- 3. 郑州大学附属肿瘤医院/河南省肿瘤医院神经外科,河南郑州 450008
- 4. 郑州大学附属肿瘤医院/河南省肿瘤医院重症医学科,河南郑州 450008
- 5. 河南省人民医院脑血管病医院神经外科ICU,河南郑州 450003
- 折叠
摘要
目的 探讨医疗失效模式与效应分析(HFMEA)在神经重症患者中心静脉血管通路装置(CVAD)医用粘胶相关性皮肤损伤(MARSI)管理中的应用效果.方法 建立神经重症CVAD-MARSI管理小组,选择河南省人民医院2023年3-6月收治的197例带有CVAD的患者作为对照组,选择2023年7-10月收治的162例带有CVAD的患者作为观察组,应用HFMEA梳理CVAD-MARSI管理流程,进行失效原因分析,计算风险指数,根据分析结果制定有效防范措施.比较两组CVAD-MARSI发生情况.结果 观察组CVAD-MARSI发生率[2.5%(4/162)]低于对照组[14.2%(28/197)](P<0.05).结论 应用HFMEA改善神经重症患者CVAD-MARSI管理流程,能够降低神经重症患者CVAD-MARSI 发生率.
Abstract
Objective To explore the application effect of health care failure mode and effect analysis(HFMEA)in the management of central venous access devices(CVAD)medical adhesive related skin injury(MARSI)of neurocritical patients.Methods A neurocritical CVAD-MARSI management team was established,197 patients with CVAD admitted to Henan Provincial People's Hospital from March to June 2023 were selected as the control group,and 162 patients with CVAD admitted from July to October 2023 were selected as the observation group.HFMEA was applied to streamline the CVAD-MARSI management process,failure cause analysis was conducted,the risk index was calculate,and effective preventive measures was developed based on the analysis results.The occurrence of CVAD-MARSI between two groups was compared.Results The incidence of CVAD-MARSI in the observation group[2.5%(4/162)]was lower than the control group[14.2%(28/197)](P<0.05).Conclusion Applying HFMEA to improve the CVAD-MARSI management process in neurocritical patients can reduce the incidence of CVAD-MARSI in critically ill patients.
关键词
医用粘胶相关性皮肤损伤/医疗失效模式与效应分析/中心静脉导管Key words
medical adhesive related skin injury/health care failure mode and effect analysis/central venous catheter引用本文复制引用
基金项目
河南省医学科技攻关计划省部共建重点项目(SBGJ202002001)
出版年
2024